Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei

doi:10.4240/wjgs.v15.i6.1149

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2605)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1318

Figures (1-3)

322

Tables (1-3)

238

Sum=1963

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

118

Download

415

Sum=533

Jun 27, 2023 (publication date) through Feb 6, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jun 27, 2023; 15(6): 1149-1158
Published online Jun 27, 2023. doi: 10.4240/wjgs.v15.i6.1149

Open in New Tab Full Size Figure Download Figure

Figure 1 Study design. A: Flow chart; B: Swimmer plot of the 32 patients. PMP: Pseudomyxoma peritonei; CC: Completeness of cytoreduction; Bev+CTX+OXA: Bevacizumab combined with cyclophosphamide and oxaliplatin; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy.

Open in New Tab Full Size Figure Download Figure

Figure 2 Progression-free survival for 32 patients. A: Total progression-free survival; B: Stratified analysis of preoperative CA125; C: Stratified analysis of completeness of cytoreduction score. PFS: Progression-free survival; CC: Completeness of cytoreduction.

Open in New Tab Full Size Figure Download Figure

Figure 3 Changes in serum tumor markers in 32 patients before and after treatment. A: Changes in CA199 before and after treatment; B: Changes in CA125 before and after treatment; C: Changes in carcinoembryonic antigen before and after treatment. CEA: Carcinoembryonic antigen.

Citation: Zhang Y, Zhao X, Gao C, Lin LY, Li Y. Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei. World J Gastrointest Surg 2023; 15(6): 1149-1158
URL: https://www.wjgnet.com/1948-9366/full/v15/i6/1149.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i6.1149